AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04023032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent cognitive intervention
Description: The intervention takes place in groups of 6-10 participants and is leaded by one occupational therapist. It includes 16 sessions, 90 minutes each.~The first part of each session starts with a 15-minute review of previous homework or relaxation. The second part, which lasts 35 minutes, involves structured training with activity-sheets, board games, role-playing and computerized games. The third part, which lasts 30 minutes, is the lifestyle interventions. The instructor explains the generalization of the previous activities toward daily life, and introduces healthy lifestyles. Through group discussions, the therapist guides participants to develop solutions and strategies for their memory or cognition-related problems and application to daily life. The last 10 minutes are used to suggest homework.
Study NCT00985387 — intervention group
Intervention type: DRUG
Intervention: Solifenacin
Description: oral
Study NCT01567917 — intervention group
Intervention type: PROCEDURE
Intervention: CRC surgery
Description: Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)~- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE
Study NCT04303806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: receive rosuvastatin orally once daily.
Study NCT03005496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: included in intervention arm
Study NCT03005496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: included in intervention and control arm
Study NCT03005496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine
Description: included in intervention and control arm
Study NCT03005496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beta Carotene
Description: included in intervention arm
Study NCT03005496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: included in intervention arm
Study NCT03005496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: included in intervention and control arm
Study NCT03005496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: included in intervention and control arm
Study NCT02535767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.
Study NCT02387671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device: FitBit Flex wrist band
Description: Participants will track their daily steps walked and hours of sleep by wearing the FitBit Flex wrist band during the 8 week study period. The data collected from the wrist band will be synced to participants' FitBit smart phone application and monitored by the study team.
Study NCT02387671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device: FitBit Aria weight scale
Description: Participants will record their daily body weight during the 8 week study period by stepping on the FitBit Aria weight scale. The data collected from the scale will be synced to participants' FitBit smart phone application accounts and monitored by the study team.
Study NCT02387671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Intake Messages
Description: The study team will send participants daily text messages regarding their dietary intake. Each message will contain five questions that yield a yes, or no response. Messages will be sent daily during the 8 week study period. Responses from the messages will be recorded and monitored by the study team to enhance the behavioral counseling intervention.
Study NCT02387671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Description: Participants will engage in four phone calls with the study counselor to discuss behavioral several topics (physical activity, sleep, fatigue \& dietary patterns) and to reflect on their data recorded by the FitBit devices. The calls will take place on a bi-weekly basis. During the weeks between calls, the counselor will maintain contact with the participants through asynchronous text messages to monitor their progress in the study.
Study NCT01695993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expectancy-enhancing handout
Description: The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
Study NCT00558467 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pramipexole immediate release (IR)
Study NCT00558467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04644302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: microcirculation recording
Description: non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws
Study NCT04340037 — intervention group
Intervention type: PROCEDURE
Intervention: percutaneous nephrolithotomy
Description: percutaneous surgery using nephroscope
Study NCT04539184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Style Acupuncture Treatment (MSAT)
Description: MSAT required a part of the patient's body to move passively or actively while acupuncture needles are retained.
Study NCT04539184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: General acupuncture
Study NCT02189005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study dietary supplement (PreCrea 600 mg capsules)
Description: Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.
Study NCT02189005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03526250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01695993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancy-enhancing MP3
Description: Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
Study NCT04299698 — intervention group
Intervention type: BEHAVIORAL
Intervention: lifestyle
Description: Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.
Study NCT04457583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with powerbreathe
Description: Participants will be submitted to a linear pressure resistance (Powerbreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 exercises for 12 weeks.
Study NCT03941990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed 50:50 mixture of nitrous oxide and oxygen
Description: Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
Study NCT03941990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inhale medical air (22% O2 - 78% N2)
Study NCT02628613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus Epirubicin
Description: Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
Study NCT02628613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel plus Epirubicin
Description: standard neoadjuvant chemotherapy
Study NCT02567227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
Study NCT02567227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Computer, multimedia and group based health education programs.
Study NCT02379078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision-making aid
Description: The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.
Study NCT02379078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Generic hard copy diabetes resources
Description: A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
Study NCT04454047 — intervention group
Intervention type: PROCEDURE
Intervention: Extracapsular arthroscopy
Description: Extracapsular arthroscopy method was used to treat refractory tennis elbow
Study NCT00951743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adaptavir (monomeric DAPTA)
Description: Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day.
Study NCT00951743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adaptavir (monomeric DAPTA)
Description: Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day.
Study NCT02402387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral head position
Study NCT02402387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexed head position
Study NCT02402387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended head position
Study NCT02402387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotated head position
Study NCT02402387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q SP Airway
Study NCT02402387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q SP Airway
Study NCT03793114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cosyntropin stimulation test
Description: Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.
Study NCT03793114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cosyntropin stimulation test
Description: Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.
Study NCT03793114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Baseline blood tests
Description: Medication-fasting morning levels of adrenocortical hormones.
Study NCT03793114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30-hour ambulatory sampling of intestinal fluid
Description: 30-hour ambulatory sampling of intestinal fluid for analysis of adrenocortical hormones.
Study NCT03793114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Cardiovascular and inflammatory biomarker profiles
Study NCT04791722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Intervention
Description: The investigators will conduct an adaptive intervention using six key implementation strategies identified in earlier research on the experiences of public housing authorities adopting a smoke-free housing policy: resident engagement, smoking cessation support, smoker compliance strategies, smoke-free policy enforcement, staff training and community partnership development. The implementation approach will be tailored for each property by varying the order and intensity of smoke-free policy implementation approaches. The design will determine the optimal plan for utilizing the six implementation strategies by learning from the challenges and successes of other properties (previous waves) and providing support to property managers to refine an implementation plan.
Study NCT01882322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: oral
Study NCT01882322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study NCT01882322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study NCT02379078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Generic online diabetes resources
Description: Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
Study NCT02745184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lung stem cells
Description: Patients will receive 0.5-5x10\^6 (0.5-5 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
Study NCT01029418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 and sorafenib
Description: dose escalation of AZD6244; sorafenib 400mg bd
Study NCT06086665 — intervention group
Intervention type: DRUG
Intervention: Niraparib
Description: Niraparib
Study NCT02103816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartLipo Triplex laser system along with the SideLaze800 hand piece
Study NCT04791722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Intervention
Description: The investigators will conduct an adaptive intervention using six key implementation strategies identified in earlier research on the experiences of public housing authorities adopting a smoke-free housing policy: resident engagement, smoking cessation support, smoker compliance strategies, smoke-free policy enforcement, staff training and community partnership development. The implementation approach will be tailored for each property by varying the order and intensity of smoke-free policy implementation approaches. The design will determine the optimal plan for utilizing the six implementation strategies by learning from the challenges and successes of other properties (previous waves) and providing support to property managers to refine an implementation plan.
Study NCT00086684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium 100 mg
Description: One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
Study NCT00086684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
Study NCT00086684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium 100 mg
Description: One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
Study NCT00433394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cancer prevention intervention
Study NCT00433394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: educational intervention
Study NCT03241862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Silk
Description: Restylane® Silk (Galderma Laboratories, L.P.) is a hyaluronic acid injectable filler, which is approved by the FDA for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids.
Study NCT02019316 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioSteel Sports Drink
Description: Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
Study NCT04160819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs.
Study NCT02019316 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isoenergetic Control
Description: Participants will ingest 500ml of Gatorade 3 times during an exercise session.
Study NCT00302328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: macular hole operation
Description: macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
Study NCT03322865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction:~Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15\*~\*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.~Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance~Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:~Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity
Study NCT02125526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-aortic balloon pump
Description: The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
Study NCT00302328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: macular hole operation
Description: macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
Study NCT03315000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol and Fluticasone Furoate
Description: Same as vilanterol arm description
Study NCT03315000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: Same as fluticasone arm description
Study NCT03208335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Description: The cycles of rh-endostatin's treatment depends on the effect of reaction and tolerance.
Study NCT02903940 — intervention group
Intervention type: DEVICE
Intervention: CRT+NAVH
Description: Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
Study NCT04351919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg per day during 10 days
Study NCT04351919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg per day during 5 days
Study NCT04143698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic retrograde cholangiopancreatography
Description: The duodenoscope will be passed to the duodenum in the standard fashion. Once the papilla has been identified in the duodenum, cannulation of the desired duct will be performed in the standard fashion, with the type of accessories used left to the discretion of the individual endoscopist performing the procedure. If cannulation is considered difficult, advanced cannulation techniques can be used per standard of care at the discretion of the individual endoscopist. The types of accessories used will be left to the discretion of the individual endoscopist and will be dependent on procedure indication and personal preference. Cross-over to the alternate duodenoscope type can be performed at any time if the desired technical maneuver cannot be performed with the designated duodenoscope.
Study NCT04558801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application-based lifestyle change program
Description: Usage of the Mobile application-based lifestyle change program
Study NCT04558801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile application-based lifestyle change program
Description: Usage of the Mobile application-based lifestyle change program
Study NCT03747133 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.
Study NCT03208166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doctormate
Description: Ischemic conditioning device